1-3 of 3
Bruce Keyt
Close
Sort by
Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

Elizabeth Budde, MDPhD, Ajay K. Gopal, MD, Ian W. Flinn, MD PhD, Loretta J. Nastoupil, MD, Michael S. Gordon, MD, Ching-Fai Pang, PhD, Bruce Keyt, PhD, Steve Carroll, PhD, Maya Leabman, PhD, Genevive Hernandez, PhD, Iris Sison, Daniel Chen, MD PhD, Wayne Godfrey, MD, Philippe Armand, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-134983
Published: 2020
Journal Articles

High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

Ramesh Baliga, PhD, Keyu Li, PhD, Marigold Manlusoc, Paul Hinton, Dean Ng, PhD, Madeline Tran, Bing Shan, PhD, Hai Lu, Avneesh Saini, PhD, Sachi Rahman, Yuan Cao, PhD, Chitra Saraiya, Marvin Peterson, PhD, Steve Carroll, PhD, Daniel Chen, MD PhD, Bruce Keyt, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1574.
https://doi.org/10.1182/blood-2019-131650
Published: 2019
Journal Articles

Generation of a Fully Human High Affinity Neutralizing Antibody Against MT-SP1/Matriptase and Its Potential Role for the Treatment of B Cell Lymphoma.

Ian N. Foltz, Stan K. Morkowski, Caroline D. Scatena, Peter Ling, Hao Li, Ying Liu, Chadwick T. King, Jaspal Kang, Kathy Manchulenko, Lisa Perkins, Sukhbir Kang, Minchao Chen, Wayne Godfrey, Bruce Keyt, Jennifer H. Richardson
Journal: Blood
Blood (2005) 106 (11): 4816.
https://doi.org/10.1182/blood.V106.11.4816.4816
Published: 2005